Recent advances in systemic therapy for hepatocellular carcinoma

被引：154

作者：

Zhang, Huajun ^{[1
]}

Zhang, Wuyang ^{[2
]}

Jiang, Longying ^{[1
,3
]}

Chen, Yongheng ^{[1
,4
]}

机构：

[1] Cent South Univ, Xiangya Hosp, Dept Oncol, NHC,Key Lab Canc Prote,Lab Struct Biol, Changsha 410008, Hunan, Peoples R China

[2] Cent South Univ, Xiangya Hosp, Clin Skills Training Ctr, Changsha 410008, Hunan, Peoples R China

[3] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China

[4] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha 410008, Hunan, Peoples R China

来源：

BIOMARKER RESEARCH | 2022年 / 10卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Hepatocellular carcinoma; Molecular targeted therapy; Immunotherapies; Combination; ENDOTHELIAL GROWTH-FACTOR; TUMOR-ASSOCIATED MACROPHAGES; RECEPTOR TYROSINE KINASES; NIVOLUMAB PLUS IPILIMUMAB; PHASE-III; DOUBLE-BLIND; OPEN-LABEL; T-CELLS; 1ST-LINE TREATMENT; ANTITUMOR-ACTIVITY;

D O I：

10.1186/s40364-021-00350-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially with conventional cytotoxic drugs, is usually ineffective. For more than a decade, sorafenib has been the only systemic drug that has been proven to be clinically effective for treating advanced HCC. However, over the past three years, the rapid progress of molecular targeted therapies has dramatically changed the treatment landscape for advanced HCC. Immune checkpoint therapies are now being incorporated into HCC therapies, and their combination with molecular targeted therapy is emerging as a tool to enhance the immune response. In this review, we summarize the development and progress of molecular targeted agents and immunotherapies in HCC.

引用

页数：21

共 154 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].

Abramson, Jeremy S. ;

Palomba, M. Lia ;

Gordon, Leo I. ;

Lunning, Matthew A. ;

Wang, Michael ;

Arnason, Jon ;

Mehta, Amitkumar ;

Purev, Enkhtsetseg ;

Maloney, David G. ;

Andreadis, Charalambos ;

Sehgal, Alison ;

Solomon, Scott R. ;

Ghosh, Nilanjan ;

Albertson, Tina M. ;

Garcia, Jacob ;

Kostic, Ana ;

Mallaney, Mary ;

Ogasawara, Ken ;

Newhall, Kathryn ;

Kim, Yeonhee ;

Li, Daniel ;

Siddiqi, Tanya .

LANCET, 2020, 396 (10254) :839-852

[3] Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes [J].

Alfaro, C. ;

Suarez, N. ;

Gonzalez, A. ;

Solano, S. ;

Erro, L. ;

Dubrot, J. ;

Palazon, A. ;

Hervas-Stubbs, S. ;

Gurpide, A. ;

Lopez-Picazo, J. M. ;

Grande-Pulido, E. ;

Melero, I. ;

Perez-Gracia, J. L. .

BRITISH JOURNAL OF CANCER, 2009, 100 (07) :1111-1119

[4] Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies [J].

Alqahtani, Ali ;

Khan, Zubair ;

Alloghbi, Abdurahman ;

Ahmed, Tamer S. Said ;

Ashraf, Mushtaq ;

Hammouda, Danae M. .

MEDICINA-LITHUANIA, 2019, 55 (09)

[5] Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].

Anderson, Ana C. ;

Joller, Nicole ;

Kuchroo, Vijay K. .

IMMUNITY, 2016, 44 (05) :989-1004

[6] Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma [J].

Ao, Jian-Yang ;

Zhu, Xiao-Dong ;

Chai, Zong-Tao ;

Cai, Hao ;

Zhang, Yuan-Yuan ;

Zhang, Ke-Zhi ;

Kong, Ling-Qun ;

Zhang, Ning ;

Ye, Bo-Gen ;

Ma, De-Ning ;

Sun, Hui-Chuan .

MOLECULAR CANCER THERAPEUTICS, 2017, 16 (08) :1544-1554

[7] Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial [J].

Bardia, A. ;

Messersmith, W. A. ;

Kio, E. A. ;

Berlin, J. D. ;

Vahdat, L. ;

Masters, G. A. ;

Moroose, R. ;

Santin, A. D. ;

Kalinsky, K. ;

Picozzi, V ;

O'Shaughnessy, J. ;

Gray, J. E. ;

Komiya, T. ;

Lang, J. M. ;

Chang, J. C. ;

Starodub, A. ;

Goldenberg, D. M. ;

Sharkey, R. M. ;

Maliakal, P. ;

Hong, Q. ;

Wegener, W. A. ;

Goswami, T. ;

Ocean, A. J. .

ANNALS OF ONCOLOGY, 2021, 32 (06) :746-756

[8] Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma [J].

Batra, Sai Arun ;

Rathi, Purva ;

Guo, Linjie ;

Courtney, Amy N. ;

Fleurence, Julien ;

Balzeau, Julien ;

Shaik, Rahamthulla S. ;

Nguyen, Thao P. ;

Wu, Meng-Fen ;

Bulsara, Shaun ;

Mamonkin, Maksim ;

Metelitsa, Leonid S. ;

Heczey, Andras .

CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) :309-320

[9]

Bi F, 2020, J CLIN ONCOL, V38

[10] Antibody-Drug Conjugate-Based Therapeutics: State of the Science [J].

Birrer, Michael J. ;

Moore, Kathleen N. ;

Betella, Ilaria ;

Bates, Richard C. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2019, 111 (06) :538-549

← 1 2 3 4 5 6 7 8 9 10 →